Related Experiment Video
Updated: Sep 12, 2025

Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping
Published on: December 8, 2023
Cortical Visual Impairment Across a Range of Neurodevelopmental Disorders: Clinical Characterization, Diagnostic Tool
Megan Abbott1,2, Katie Angione1,2, Megan Stringfellow3
1Precision Medicine Institute, Children's Hospital Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Insights
Cortical visual impairment affects 44% of children with certain neurogenetic disorders, particularly STXBP1 and 8p-related conditions. Early detection through tools like the CDKL5-Clinical Severity Assessment is crucial for better developmental outcomes.
Area of Science:
- Neuroscience
- Genetics
- Ophthalmology
Background:
- Cortical visual impairment (CVI) is a significant concern in pediatric neurodevelopmental disorders but is often underdiagnosed.
- Understanding CVI prevalence in specific neurogenetic conditions is essential for targeted interventions.
Purpose of the Study:
- To determine the prevalence and severity of CVI in STXBP1, SLC6A1, Ring 14, and 8p-related disorders.
- To evaluate the CDKL5-Clinical Severity Assessment-Clinician vision subdomain as a diagnostic tool for CVI.
- To examine the relationship between CVI and developmental outcomes in these patient populations.
Main Methods:
- Retrospective chart review of 85 patients with STXBP1, SLC6A1, Ring 14, or 8p-related disorders.
- Assessment of CVI using the CDKL5-Clinical Severity Assessment-Clinician vision subdomain.
- Correlation analysis between CVI, CDKL5 scores, and Vineland Adaptive Behavioral Scales-Third Edition (VABS-3) scores.
Main Results:
- CVI was identified in 44% of patients, with the highest prevalence in 8p disorders (54%) and STXBP1 disorders (50%).
- No CVI cases were observed in the SLC6A1 disorder group.
- The CDKL5-Clinical Severity Assessment-Clinician vision subdomain effectively identified CVI (mean score 25.9 vs 2.6, P < .0001), with a cutoff score ≥11 demonstrating high specificity (95.9%) and positive predictive value (94.3%).
- CVI was significantly associated with poorer developmental outcomes, indicated by higher CDKL5 scores and lower VABS-3 scores.
Conclusions:
- CVI is prevalent in specific neurogenetic disorders and is linked to adverse developmental trajectories.
- The CDKL5-Clinical Severity Assessment-Clinician vision subdomain is a valuable tool for diagnosing CVI in this population.
- Systematic screening for CVI in children with neurogenetic conditions is recommended to facilitate early intervention and improve outcomes.
Abstract:
Cortical visual impairment is particularly relevant in children with neurodevelopmental disorders yet remains underdiagnosed. This study assessed the prevalence and severity of cortical visual impairment in 4 neurogenetic conditions: STXBP1, SLC6A1, Ring 14, and 8p-related disorders. We also evaluated the CDKL5-Clinical Severity Assessment-Clinician vision subdomain as a diagnostic tool and examined the association between cortical visual impairment and developmental outcomes. A retrospective chart review of 85 patients found cortical visual impairment in 44%, most commonly in 8p (54%) and STXBP1 (50%); no cases were seen in SLC6A1. The CDKL5-Clinical Severity Assessment-Clinician vision subdomain effectively distinguished cortical visual impairment cases (mean score 25.9 vs 2.6, P < .0001). A cutoff score ≥11 showed high specificity (95.9%) and positive predictive value (94.3%). Cortical visual impairment was significantly associated with greater developmental impairment, with higher overall CDKL5-Clinical Severity Assessment-Clinician scores and lower Vineland Adaptive Behavioral Scales-Third Edition scores. Early identification of cortical visual impairment is critical for ensuring access to appropriate therapies and therefore should be more systematically evaluated for in neurogenetic conditions.
Related Concept Videos
Learning Disabilities
Dyslexia
Dyslexia is a...
Visual Agnosia
Prosopagnosia
Glaucoma: Overview
Photoreceptors and Visual Pathways
Aneurysm II: Clinical Manifestations and Diagnostic Studies

